The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma.
| Autor: | Romanos-Sirakis E; Division of Pediatric Hematology/Oncology.; Zucker School of Medicine at Hofstra/Northwell., Doan A; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA., Bittman ME; Department of Radiology, New York University Langone Medical Center., Webb RL; Department of Radiology, Staten Island University Hospital, Northwell Health, Staten Island., Williamson AK; Department of Pathology.; Zucker School of Medicine at Hofstra/Northwell., Edelman M; Department of Pathology.; Zucker School of Medicine at Hofstra/Northwell., Hanson D; Division of Pediatric Hematology/Oncology, Hackensack University Medical Center, Hackensack, NJ., Riely GJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York., Fein Levy C; Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center of New York, New Hyde Park, NY.; Zucker School of Medicine at Hofstra/Northwell. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Mar 01; Vol. 44 (2), pp. e605-e608. |
| DOI: | 10.1097/MPH.0000000000002312 |
| Abstrakt: | Background: Thymic carcinomas are rare aggressive mediastinal tumors with a median survival of 2 years. Observation: We present a pediatric patient who was diagnosed with metastatic thymic carcinoma and showed continuous improvement of his primary mass and lung metastases with a regimen of cisplatin/docetaxel followed by long-term maintenance therapy with sunitinib for over 5 years. Conclusions: This report demonstrates a long-term positive treatment effect using chemotherapy followed by sunitinib in an advanced thymic carcinoma. We are not aware of other reports of pediatric patients with metastatic thymic carcinoma treated with sunitinib maintenance who maintained a durable response for this prolonged period of time. Competing Interests: The authors declare no conflict of interest. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|